Egalet Corporation announced that data on ARYMO® ER (morphine sulfate) extended-release (ER) tablets for oral use only –CII was published online in the Current Medical Research and Opinion journal. ARYMO ER, formulated with Egalet's Guardian™ Technology, is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The publication include: In human abuse potential (HAP) studies of abuse-deterrent (AD) opioids, characteristics of the non-AD comparator such as the formulation (e.g., immediate-release or extended-release) and the dose can potentially influence HAP study results; How an AD opioid and its non-AD comparators are manipulated, the amount of active drug that can be extracted following manipulation, and the ways in which treatments are given such as in a solution versus swallowing the manipulated product with liquid can impact the outcomes of HAP studies; and There may be AD opioids where the retrospective assessments of Overall Drug Liking and/or Take Drug Again may not be as sensitive and/or predictive of the risk for misuse and abuse and, thus, less useful for determining the overall abuse deterrence profile of that AD opioid; and Tailoring the choices of the most appropriate primary and secondary endpoints of HAP studies to the specific AD technology/approach for the opioid under investigation may provide better insight into the potential of a particular AD product to deter abuse in real-world settings.